ChonlutenLongevity
Khavinson tripeptide bioregulator studied for bronchial and respiratory tissue.
Overview
Chonluten is a synthetic tripeptide, glutamate-aspartate-glycine (Glu-Asp-Gly / EDG), from Vladimir Khavinson's peptide-bioregulator family, presented by its developers as a regulator of bronchial (respiratory-tract) tissue. The indexed evidence is very thin: a single 2022 cell-culture study in which it reduced inflammatory TNF release from stimulated monocytes, plus review articles by the originating group that describe unindexed Russian clinical use in chronic bronchitis. The group's own papers are not even consistent about its target, calling it bronchoprotective in some and gastro- and stress-protective in others. There are no independent human trials; it is not FDA-evaluated and is sold only as a research chemical.
Evidence
Anecdotal reports community-reported
What people describe in forums, blogs and uncontrolled clinic write-ups — experiential and unverified, not clinical evidence and not medical advice.
- Single first-hand report: lung function with Bronchogen for Long COVIDa single detailed report
The only first-hand mention found is a user running Chonluten and Bronchogen together, both injectable at 1 mg/day, for Long COVID, who says they have felt their lung function improve; no duration, follow-up or measurements are given, and the two peptides cannot be separated. The one other Chonluten question, from a 20-year smoker wanting a protocol, drew only advice to see a respiratory specialist and get screened.
Sources
Starting references for the library summary. These are not dosing instructions or medical advice.
Prices
Compare Chonluten prices across vendors.
Compare prices — from $45.00For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.